TH181225A - - Google Patents
Info
- Publication number
- TH181225A TH181225A TH1701007845A TH1701007845A TH181225A TH 181225 A TH181225 A TH 181225A TH 1701007845 A TH1701007845 A TH 1701007845A TH 1701007845 A TH1701007845 A TH 1701007845A TH 181225 A TH181225 A TH 181225A
- Authority
- TH
- Thailand
- Prior art keywords
- pharmaceutical
- page
- losartan
- amlodipine
- rosuvastate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract 6
- 239000002083 C09CA01 - Losartan Substances 0.000 claims abstract 5
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960004773 Losartan Drugs 0.000 claims abstract 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960000528 amlodipine Drugs 0.000 claims abstract 4
- 239000005426 pharmaceutical component Substances 0.000 claims abstract 4
- 239000002245 particle Substances 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract 2
- 230000036912 Bioavailability Effects 0.000 claims abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims abstract 2
- 201000001320 atherosclerosis Diseases 0.000 claims abstract 2
- 230000035514 bioavailability Effects 0.000 claims abstract 2
- 239000000306 component Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- 238000005020 pharmaceutical industry Methods 0.000 claims abstract 2
- 229960000672 rosuvastatin Drugs 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
Abstract
หน้า 1 ของจำนวน 1 หน้า บทสรุปการประดิษฐ์ ที่ได้เปิดเผยไว้คือองค์ประกอบทางเภสัชกรรมเพื่อการป้องกันหรือการรักษาโรคหลอดเลือด หัวใจที่ประกอบรวมด้วยแอมโลดิพีน, โรซูวาสเททีน และลอซาร์แทน และสูตรผสมเชิงซ้อนทาง เภสัชกรรมที่ประกอบรวมด้วยส่วนของของผสมแรกที่มีแอมโลดิพีนและโรซูวาสเททีนและส่วนของ ของผสมที่สองที่มีลอซาร์แทน องค์ประกอบหรือสูตรผสมเชิงซ้อนที่ประกอบรวมด้วยโรซูวาสเททีน นี้มีขนาดอนุภาค (D90) เป็น 50 สัญลักษณ์ เมตร หรือน้อยกว่า และแสดงออกถึงอัตราการละลาย, ชีวปริมาณ ออกฤทธิ์, เสถียรภาพและความเป็นเอกรูปของส่วนประกอบที่ดีเลิศ และด้วยเหตุนี้จึงอาจมีประโยชน์ ในอุตสาหกรรมทางเภสัชกรรม สิทธิบัตรยา 1 page of the number 1 page summary of the invention The disclosed are the pharmaceutical components for the prevention or treatment of atherosclerosis. The heart is made up of amlodipine, rosuvastetine and losartan and a complex formulation. A pharmaceutical consisting of a first mixture containing amlodipine and rosuvastate and a portion of The second mix with losartan Elements or complex formulas containing rosuvastatin This has a particle size (D90) of 50 meters or less and represents excellent solubility, bioavailability, stability and component integrity. And for that it might be useful In the pharmaceutical industry, drug patents
Claims (2)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH181225A true TH181225A (en) | 2018-11-08 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201908427B (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
| IL262495B (en) | Isoquinoline-3-carboxamide derivatives and pharmaceutical compositions comprising them | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| EP3347022A4 (en) | Pharmaceutical composition including dutasteride and capsule formulation comprising the same | |
| Tousoulis et al. | Impact of folic acid administration in homocysteine levels, inflammation and in atherosclerotic plaque area in apoE deficient mice | |
| TH181225A (en) | ||
| HUE066663T2 (en) | Pharmaceutical formulation with improved solubility and bioavailability | |
| TH173709A (en) | Pladienolide compounds Pyridine and methods of use | |
| TH171506A (en) | Pharmaceutical composition, low dose | |
| TH168790A (en) | The new combination between 8-cyclopropyl -3- [2- (3- fluorophenyl) ethyl] -7,8-dihydro -3H- [1,3] oxasino [6, 5-g] [1,2,3] benzotriazine -4,9-dion and acetylcholine esterase inhibitor, and the pharmaceutical constituents that have this | |
| Gualano et al. | Comment on" Toxic hepatitis in a group of 20 male body-builders taking dietary supplements" by Timcheh-Hariri et al.(2012), Food and Chemical Toxicology 50, 3826-3832: alleged adverse effects of creatine supplementation and the lack of appreciation of the wide gap between experimental and clinical studies | |
| TH151384A (en) | Pharmaceutical components containing drugs with low water solubility. | |
| TH1701006437A (en) | Azabenzimidazole and its use as AMPA receptor modulator. | |
| TH156552A (en) | Phenoxyethylpiperidine Compound | |
| TH170803A (en) | Pharmaceutical combination drugs | |
| GB201702831D0 (en) | Estate agent advertising boards displaying the marketing price of the property, for sale and for letting | |
| TH1701003406A (en) | Pharmaceutical formulation of tropomieosin-related kinase inhibitors (TRK). | |
| TH1801004071A (en) | Anticancer substances | |
| IT201700111228A1 (en) | Polyester based excipients for the formulation of lipophilic drugs within nanoparticles and the method for their production | |
| TH1801003854A (en) | Pharmaceutical composite preparations | |
| TH1601006537A (en) | Thyaminopirimidine compounds, useful for prevention Or cure malaria | |
| TH168000A (en) | An amorphous solid dispersant consisting of a flat tablet tagane. Which includes the said substances and methods for their preparation | |
| TH1801002665A (en) | Compound 7- (thiazol-5-il) pyrolopyrimidine is TLR7 agonist. | |
| TH1801001808A (en) | An isoindolinone inhibitor of MDM2-P53 interaction with anticancer activity. | |
| TH153609A (en) | New types of thiopyrimidine derivatives, the preparation process of these derivatives, and the pharmaceutical constituents that comprise them. |